(Natural News) Pfizer executives are making plans to raise prices on their experimental covid vaccine once the pandemic messaging ends. When the World Health Organization claims the pandemic is under control, Pfizer still has plans to profit from covid-19 every year, into perpetuity. A virtual conference hosted by Barclays revealed the ill-gotten plans of investors and top Pfizer executives, as they continue to plot their next business moves.
In the virtual conference, Carter Lewis Gould, a senior analyst for Barclay’s Biopharma Equity Research, referenced a conversation with Pfizer executives that took place in the summer of 2020. According to the transcribed conversation, the Pfizer executives are looking forward to jacking up the price of their vaccines once the “pandemic” becomes endemic and is labeled “a seasonal illness.”
Experimental vaccines and PCR tests for coronavirus are designed for perpetual profits, not public health
The emergency use “pandemic” vaccines are not designed to eradicate covid-19 completely. According to former Pfizer executive Dr. Michael Yeadon, the study designs for the new vaccines are fraudulent and do not properly diagnose covid-19 using the Sanger Sequencing method. This false advertisement of vaccine efficacy allows Pfizer to gain emergency use approval from regulatory agencies around the world, even as people continue to get sick (and sometimes die) after vaccination. Despite it’s promises of efficacy, this medical fraud will fail to prevent respiratory infections and will ultimately drive the need for more vaccine updates and more boosters, guaranteeing profits for Pfizer and other vaccine maker’s long term. This is also why coronavirus PCR testing is being incorporated as a rite of passage on airlines, events, cruises, etc. The tests (and all their false positives) guarantee a set number of “covid-19 cases” that will enable continuous media fear campaigns that will ultimately be used to feed the need for routine, seasonal vaccination.
Gould questioned the business plans of Frank A. D’Amelio, CFO & executive VP of global supply for Pfizer. D’Amelio said Pfizer anticipates a “significant opportunity” for their vaccines “from a pricing perspective” once the situation turns “from a pandemic situation to an endemic situation.”
From the mouth of D’Amelio:
“So if you look at how current demand and current pricing is being driven, it’s clearly not being driven by what I’ll call normal market conditions, normal market forces. It’s really been driven by kind of the pandemic state that we’ve been in and the needs of governments to really secure doses from the various vaccine suppliers,” D’Amelio explained. “So what we believe, what I believe is as we move from a pandemic state, from a pandemic situation to an endemic situation, normal market forces, normal market conditions will start to kick in.”
D’Amelio said that the vaccine’s efficacy is a factor that will “become very important.” If the efficacy is low, then there will be opportunities to sell booster shots. He said that “booster ability” will also be a very important factor. He said “efficacy, booster ability, and clinical utility” present “a significant opportunity for our vaccine from a demand perspective, from a pricing perspective, given the clinical profile of our vaccine.” He said there’s “more to come here” because the pandemic will ultimately be declared endemic, providing more opportunities for Pfizer to profit long term.
Pfizer executives planning to introduce seasonal mRNA vaccines for coronavirus and influenza
The federal government has already redistributed multiple billions of dollars in taxpayer money to Pfizer so Americans can get “free” covid-19 vaccines. Pfizer walked away with $1.95 billion in taxpayer dollars last July after contracting with the federal government. In December, Pfizer inked another $2 billion deal, as taxpayers were forced to subsidize the experiment further.
Once the CDC’s phased rollout of the vaccine is complete, the Department of Health and Human Services will decide whether to continue on with pandemic messaging. The current nominee to head the department, Xavier Becerra, will be pressured to end pandemic messaging so Pfizer and other vaccine makers can profit indefinitely. After the CDC’s phased vaccine rollout is complete, Pfizer will need a new way to guarantee a revenue stream, and they are positioned to capitalize.
According to transcripts between Pfizer executives and investors, the vaccine maker is also looking to get into the flu vaccine market using experimental mRNA vaccines for influenza strains. In January 2021, the WHO updated their recommendations to labs around the world, instructing them to lower the cycle count for PCR tests in order to lower the number of false positives. As this new policy sets in, the number of covid cases will come down, clearing the way for the “pandemic” to be declared a seasonal illness. As the vaccinated continue to seek hospitalization for respiratory illness, Pfizer and the rest of the vaccine industry will continue to exploit the world population with new mRNA updates and calls for mandatory vaccination via vaccine passports and the stripping exemptions. It’s a vicious cycle of fraud, malfeasance and human exploitation.